07 Oct 2026, 15:25 IST
Eris Lifesciences Limited
HDFC Securities · BUY · target Rs 1,730
The report expects 13% YoY revenue growth led by India chronic therapies and the Semaglutide launch, naming it among strong performers.
From Pharma and Healthcare Q2FY27 Preview HSIE, written by HDFC Securities. Orivam summarised it; the view is HDFC Securities's, not Orivam's.
Open the original PDF →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.